The Clinical Sample Acquisition and Repository Scientific Research Support Component (SRSC) will provide human clinical samples required for the studies outlined in the CHAVI-ID research plan. One key goal of CHAVI-ID is to study subjects that make broad neutralizing antibodies (BnAbs) in order to understand how best to induce BnABs. Another key goal is to receive vaccine trial samples from collaborating networks and to provide these samples to CHAVI-ID investigators. The clinical samples that are needed for the B, T and Innate cell studies as well as studies in the SRSCs, are those from chronically infected subjects who have been extensively characterized for their ability to make broad neutralizing antibodies (BnAbs), and samples from HIV-1 vaccine trials carried out by the HIV Vaccine Trials Network (HVTN), the Military HIV Research Program (MHRP) or the NIH Vaccine Research Center (VRC) as well as control samples. It is also important to have a sample repository comprised of both samples from control groups, samples from volunteers in vaccine trials as well as samples from both acute and chronic HIV-1 infection cohorts, such that when opportunities arise to test new hypotheses that require clinical material, CHAVI-ID research can move quickly ahead without stopping to write and get new clinical protocols approved.
Specific Aims Aim 1. To recruit and maintain the CHAVI-ID clinical sites for CHAVI-ID studies.
Aim 2. To maintain high quality specimen processing laboratories at the CHAVI-ID sites to ensure the highest quality sample acquisition.
Aim 3. To maintain CHAVI-ID repository sample storage facilities for distribution to CHAVI-ID investigators.
Access to HIV-infected patients followed over time is essential to understanding the immunology of HlV-1 infection. Having experienced and skilled clinical research personnel is essential for obtaining and maintaining high quality clinical specimens to support the research that can lead to successful vaccine design.
|Pardi, Norbert; Hogan, Michael J; Naradikian, Martin S et al. (2018) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215:1571-1588|
|Eudailey, Joshua A; Dennis, Maria L; Parker, Morgan E et al. (2018) Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. mSphere 3:|
|Kelsoe, Garnett; Haynes, Barton F (2018) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol 10:|
|Wagh, Kshitij; Kreider, Edward F; Li, Yingying et al. (2018) Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Rep 25:893-908.e7|
|Fu, Qingshan; Shaik, Md Munan; Cai, Yongfei et al. (2018) Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A 115:E8892-E8899|
|Fera, Daniela; Lee, Matthew S; Wiehe, Kevin et al. (2018) HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. Nat Commun 9:1111|
|McMichael, Andrew J (2018) Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? Could a CD8+ T-Cell Vaccine Prevent Persistent HIV Infection? Cold Spring Harb Perspect Biol 10:|
|Williams, Wilton B; Han, Qifeng; Haynes, Barton F (2018) Cross-reactivity of HIV vaccine responses and the microbiome. Curr Opin HIV AIDS 13:9-14|
|Bonsignori, Mattia; Scott, Eric; Wiehe, Kevin et al. (2018) Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity 49:1162-1174.e8|
|Blasi, Maria; Negri, Donatella; LaBranche, Celia et al. (2018) IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Commun Biol 1:134|
Showing the most recent 10 out of 261 publications